Novel indole-2-carboxamide compounds are potent broad-spectrum antivirals active against western equine encephalitis virus in vivo

Journal of Virology

Volumn 88, Issue 19, 2014, Pages 11199-11214

  Delekta, Phillip C ^a   Dobry, Craig J ^a   Sindac, Janice A ^b   Barraza, Scott J ^b   Blakely, Pennelope K ^a   Xiang, Jianming ^a   Kirchhoff, Paul D ^b   Keep, Richard F ^a   Irani, David N ^a   Larsen, Scott D ^b   Miller, David J ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIDE; ANTIVIRUS AGENT; CCG 205432; CCG 206381; CCG 209023; RIBAVIRIN; UNCLASSIFIED DRUG; VIRUS RNA; CCG205432; INDOLE DERIVATIVE; PYRIDINE DERIVATIVE;

ALPHAVIRUS INFECTION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIVIRAL ACTIVITY; ARTICLE; BUNYAVIRUS; CELL ASSAY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DISEASE SEVERITY; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; DRUG RESEARCH; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG TARGETING; DRUG TOLERABILITY; FEMALE; HUMAN; HUMAN CELL; IC50; IN VIVO STUDY; MOUSE; NERVE CELL CULTURE; NONHUMAN; NUCLEOTIDE SEQUENCE; OVERALL SURVIVAL; PARAMYXOVIRUS; PICORNAVIRUS; REPLICON; SURVIVAL RATE; SURVIVAL TIME; TOGAVIRUS; TRANSLATION REGULATION; TREATMENT DURATION; VIRUS CELL INTERACTION; VIRUS ENCEPHALITIS; WESTERN EQUINE ENCEPHALOMYELITIS ALPHAVIRUS; ANIMAL; C57BL MOUSE; CELL LINE; DRUG EFFECT; GROWTH, DEVELOPMENT AND AGING; IC 50; MORTALITY; NERVE CELL; PATHOGENICITY; PROTEIN SYNTHESIS; STRUCTURE ACTIVITY RELATION; SURVIVAL; SYNTHESIS; VIROLOGY; VIRUS REPLICATION;

ANIMALS; ANTIVIRAL AGENTS; BUNYAVIRIDAE; CELL LINE; ENCEPHALITIS VIRUS, WESTERN EQUINE; ENCEPHALOMYELITIS, EQUINE; FEMALE; INDOLES; INHIBITORY CONCENTRATION 50; MICE; MICE, INBRED C57BL; NEURONS; PARAMYXOVIRIDAE; PICORNAVIRIDAE; PROTEIN BIOSYNTHESIS; PYRIDINES; REPLICON; STRUCTURE-ACTIVITY RELATIONSHIP; SURVIVAL ANALYSIS; VIRUS REPLICATION;

EID: 84906968949     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.01671-14     Document Type: Article

References (70)

1. Weaver SC, Reisen WK. 2010. Present and future arboviral threats. Antiviral Res. 85:328-345. http://dx.doi.org/10.1016/j.antiviral.2009.10.008.
2. Enserink M. 2007. Infectious diseases. Chikungunya: no longer a third world disease. Science 318:1860-1861. http://dx.doi.org/10.1126/science.318.5858.1860.
3. Nash D, Mostashari F, Fine A, Miller J, O'Leary D, Murray K, Huang A, Rosenberg A, Greenberg A, Sherman M, Wong S, Layton M. 2001. The outbreak of West Nile virus infection in the New York City area in 1999. N. Engl. J. Med. 344:1807-1814. http://dx.doi.org/10.1056/NEJM200106143442401.
4. Griffin DE. 2007. Alphaviruses, p 1023-1067. In Knipe DM, Howley PM, Griffin DE, Lamb RA, Martin MA, Roizman B, Straus SE (ed), Fields virology, 5th ed. Lippincott Williams & Wilkins, Philadelphia, PA.
5. Aguilar MJ. 1970. Pathological changes in brain and other target organs of infant and weanling mice after infection with non-neuroadapted western equine encephalitis virus. Infect. Immun. 2:533-542.
6. Zlotnik I, Peacock S, Grant DP, Batter-Hatton D. 1972. The pathogen-esis of western equine encephalitis virus (W.E.E.) in adult hamsters with special reference to the long and short term effects on the C.N.S. of the attenuated clone 15 variant. Br. J. Exp. Pathol. 53:59-77.
7. Liu C, Voth DW, Rodina P, Shauf LR, Gonzalez G. 1970. A comparative study of the pathogenesis of western equine and eastern equine encephalomyelitis viral infections in mice by intracerebral and subcutaneous inoculations. J. Infect. Dis. 122:53-63. http://dx.doi.org/10.1093/infdis/122.1-2.53.
8. Steele KE, Twenhafel NA. 2010. Review paper: pathology of animal models of alphavirus encephalitis. Vet. Pathol. 47:790-805. http://dx.doi.org /10.1177/0300985810372508.
9. Deresiewicz RL, Thaler SJ, Hsu L, Zamani AA. 1997. Clinical and neuroradiographic manifestations of eastern equine encephalitis. N. Engl. J. Med. 336:1867-1874. http://dx.doi.org/10.1056/NEJM199706263362604.
10. Earnest MP, Goolishian HA, Calverley JR, Hayes RO, Hill HR. 1971. Neurologic, intellectual, and psychologic sequelae following western encephalitis. A follow-up study of 35 cases. Neurology 21:969-974.
11. Wolfe DN, Florence W, Bryant P. 2013. Current biodefense vaccine programs and challenges. Hum. Vaccin. Immunother. 9:1591-1597. http: //dx.doi.org/10.4161/hv.24063.
12. Bronze MS, Greenfield RA. 2003. Therapeutic options for diseases due to potential viral agents of bioterrorism. Curr. Opin. Investig. Drugs 4:172-178.
13. Sindac JA, Yestrepsky BD, Barraza SJ, Bolduc KL, Blakely PK, Keep RF, Irani DN, Miller DJ, Larsen SD. 2012. Novel inhibitors of neurotropic alphavirus replication that improve host survival in a mouse model of acute viral encephalitis. J. Med. Chem. 55:3535-3545. http://dx.doi.org/10 .1021/jm300214e.
14. Li Y, Wang L, Li S, Chen X, Shen Y, Zhang Z, He H, Xu W, Shu Y, Liang G, Fang R, Hao X. 2007. Seco-pregnane steroids target the subgenomic RNA of alphavirus-like RNA viruses. Proc. Natl. Acad. Sci. U. S. A. 104:8083-8088. http://dx.doi.org/10.1073/pnas.0702398104.
15. Julander JG, Smee DF, Morrey JD, Furuta Y. 2009. Effect of T-705 treatment on western equine encephalitis in a mouse model. Antiviral Res. 82:169-171. http://dx.doi.org/10.1016/j.antiviral.2009.02.201.
16. Julander JG, Bowen RA, Rao JR, Day C, Shafer K, Smee DF, Morrey JD, Chu CK. 2008. Treatment of Venezuelan equine encephalitis virus infection with (-)-carbodine. Antiviral Res. 80:309-315. http://dx.doi.org/10 .1016/j.antiviral.2008.07.002.
17. Raveh A, Delekta PC, Dobry CJ, Peng W, Schultz PJ, Blakely PK, Tai AW, Matainaho T, Irani DN, Sherman DH, Miller DJ. 2013. Discovery of potent broad spectrum antivirals derived from marine actinobacteria. PLoS One 8:e82318. http://dx.doi.org/10.1371/journal.pone.0082318.
18. Reichert E, Clase A, Bacetty A, Larsen J. 2009. Alphavirus antiviral drug development: scientific gap analysis and prospective research areas. Biosecur. Bioterror. 7:413-427. http://dx.doi.org/10.1089/bsp.2009.0032.
19. Peng W, Peltier DC, Larsen MJ, Kirchhoff PD, Larsen SD, Neubig RR, Miller DJ. 2009. Identification of thieno[3,2-b]pyrrole derivatives as novel small molecule inhibitors of neurotropic alphaviruses. J. Infect. Dis. 199:950-957. http://dx.doi.org/10.1086/597275.
20. Sindac JA, Barraza SJ, Dobry CJ, Xiang J, Blakely PK, Irani DN, Keep RF, Miller DJ, Larsen SD. 2013. Optimization of novel indole-2-carboxamide inhibitors of neurotropic alphavirus replication. J. Med. Chem. 56:9222-9241. http://dx.doi.org/10.1021/jm401330r.
21. Fayzulin R, Gorchakov R, Petrakova O, Volkova E, Frolov I. 2005. Sindbis virus with a tricomponent genome. J. Virol. 79:637-643. http://dx .doi.org/10.1128/JVI.79.1.637-643.2005.
22. Ubol S, Levine B, Lee SH, Greenspan NS, Griffin DE. 1995. Roles of immunoglobulin valency and the heavy-chain constant domain in antibody-mediated downregulation of Sindbis virus replication in persistently infected neurons. J. Virol. 69:1990-1993.
23. Castorena KM, Peltier DC, Peng W, Miller DJ. 2008. Maturationdependent responses of human neuronal cells to western equine encephalitis virus infection and type I interferons. Virology 372:208-220. http: //dx.doi.org/10.1016/j.virol.2007.10.025.
24. Peltier DC, Simms A, Farmer JR, Miller DJ. 2010. Human neuronal cells possess functional cytoplasmic and TLR-mediated innate immune pathways influenced by phosphatidylinositol-3 kinase signaling. J. Immunol. 184:7010-7021. http://dx.doi.org/10.4049/jimmunol.0904133.
25. Peltier DC, Lazear HM, Farmer JR, Diamond MS, Miller DJ. 2013. Neurotropic arboviruses induce interferon regulatory factor 3-mediated neuronal responses that are cytoprotective, interferon independent, and inhibited by western equine encephalitis virus capsid. J. Virol. 87:1821-1833.http://dx.doi.org/10.1128/JVI.02858-12.
26. Barton DJ, Sawicki SG, Sawicki DL. 1991. Solubilization and immunoprecipitation of alphavirus replication complexes. J. Virol. 65:1496-1506.
27. Farmer JR, Altschaefl KM, O'Shea KS, Miller DJ. 2013. Activation of the type I interferon pathway is enhanced in response to human neuronal differentiation. PLoS One 8:e58813. http://dx.doi.org/10.1371/journal .pone.0058813.
28. Bianchi TI, Aviles G, Sabattini MS. 1997. Biological characteristics of an enzootic subtype of western equine encephalomyelitis virus from Argentina. Acta Virol. 41:13-20.
29. Diamond MS, Zachariah M, Harris E. 2002. Mycophenolic acid inhibits dengue virus infection by preventing replication of viral RNA. Virology 304:211-221. http://dx.doi.org/10.1006/viro.2002.1685.
30. Takhampunya R, Ubol S, Houng HS, Cameron CE, Padmanabhan R.Inhibition of dengue virus replication by mycophenolic acid and ribavirin. J. Gen. Virol. 87:1947-1952. http://dx.doi.org/10.1099/vir.0 .81655-0.
31. Frolov I, Frolova E, Schlesinger S. 1997. Sindbis virus replicons and Sindbis virus: assembly of chimeras and of particles deficient in virus RNA. J. Virol. 71:2819-2829.
32. Pushko P, Parker M, Ludwig GV, Davis NL, Johnston RE, Smith JF. Replicon-helper systems from attenuated Venezuelan equine encephalitis virus: expression of heterologous genes in vitro and immunization against heterologous pathogens in vivo. Virology 239:389-401. http: //dx.doi.org/10.1006/viro.1997.8878.
33. Hahn CS, Lustig S, Strauss EG, Strauss JH. 1988. Western equine encephalitis virus is a recombinant virus. Proc. Natl. Acad. Sci. U. S. A. 85:5997-6001. http://dx.doi.org/10.1073/pnas.85.16.5997.
34. Lin K, Gallay P. 2013. Curing a viral infection by targeting the host: the example of cyclophilin inhibitors. Antiviral Res. 99:68-77. http://dx.doi .org/10.1016/j.antiviral.2013.03.020.
35. Harper S, Pacini B, Avolio S, Di Filippo M, Migliaccio G, Laufer R, De Francesco R, Rowley M, Narjes F. 2005. Development and preliminary optimization of indole-N-acetamide inhibitors of hepatitis C virus NS5B polymerase. J. Med. Chem. 48:1314-1317. http://dx.doi.org/10.1021 /jm049122i.
36. Ontoria JM, Martin Hernando JI, Malancona S, Attenni B, Stansfield I, Conte I, Ercolani C, Habermann J, Ponzi S, Di Filippo M, Koch U, Rowley M, Narjes F. 2006. Identification of thieno[3,2-b]pyrroles as allosteric inhibitors of hepatitis C virus NS5B polymerase. Bioorg. Med. Chem. Lett. 16: 4026-4030. http://dx.doi.org/10.1016/j.bmcl.2006.05.012.
37. Takehara M. 1971. Comparative studies on nucleic acid synthesis and virus-induced RNA polymerase activity in mammalian cells infected with certain arboviruses. Arch. Gesamte Virusforsch. 34:266-277. http://dx .doi.org/10.1007/BF01242972.
38. Fukushi S, Kojima S, Takai R, Hoshino FB, Oka T, Takeda N, Katayama K, Kageyama T. 2004. Poly(A)-and primer-independent RNA polymerase of norovirus. J. Virol. 78:3889-3896. http://dx.doi.org/10.1128 /JVI.78.8.3889-3896.2004.
39. Li ML, Lin YH, Simmonds HA, Stollar V. 2004. A mutant of Sindbis virus which is able to replicate in cells with reduced CTP makes a replicase/ transcriptase with a decreased Km for CTP. J. Virol. 78:9645-9651. http: //dx.doi.org/10.1128/JVI.78.18.9645-9651.2004.
40. Lin YH, Yadav P, Ravatn R, Stollar V. 2000. A mutant of Sindbis virus that is resistant to pyrazofurin encodes an altered RNA polymerase. Virology 272:61-71. http://dx.doi.org/10.1006/viro.2000.0329.
41. Scheidel LM, Stollar V. 1991. Mutations that confer resistance to mycophenolic acid and ribavirin on Sindbis virus map to the nonstructural protein nsP1. Virology 181:490-499. http://dx.doi.org/10.1016/0042 -6822(91)90881-B.
42. Malinoski F, Stollar V. 1981. Inhibitors of IMP dehydrogenase prevent Sindbis virus replication and reduceGTPlevels in Aedes albopictus cells. Virology 110:281-289. http://dx.doi.org/10.1016/0042-6822(81)90060-X.
43. Chou TC. 2006. Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol. Rev. 58:621-681. http://dx.doi.org/10.1124/pr.58.3.10.
44. Walsh D, Mohr I. 2011. Viral subversion of the host protein synthesis machinery. Nat. Rev. Microbiol. 9:860-875. http://dx.doi.org/10.1038 /nrmicro2655.
45. Wang QY, Kondreddi RR, Xie X, Rao R, Nilar S, Xu HY, Qing M, Chang D, Dong H, Yokokawa F, Lakshminarayana SB, Goh A, Schul W, Kramer L, Keller TH, Shi PY. 2011. A translation inhibitor that sup-presses dengue virus in vitro and in vivo. Antimicrob. Agents Chemother. 55:4072-4080. http://dx.doi.org/10.1128/AAC.00620-11.
46. Elroy-Stein O, Fuerst TR, Moss B. 1989. Cap-independent translation of mRNA conferred by encephalomyocarditis virus 5= sequence improves the performance of the vaccinia virus/bacteriophage T7 hybrid expression system. Proc. Natl. Acad. Sci. U. S. A. 86:6126-6130. http://dx.doi.org/10 .1073/pnas.86.16.6126.
47. Bochkov YA, Palmenberg AC. 2006. Translational efficiency of EMCV IRES in bicistronic vectors is dependent upon IRES sequence and gene location. Biotechniques 41:283-284. http://dx.doi.org/10.2144/000112243.
48. Bordeleau ME, Mori A, Oberer M, Lindqvist L, Chard LS, Higa T, Belsham GJ, Wagner G, Tanaka J, Pelletier J. 2006. Functional characterization of IRESes by an inhibitor of theRNAhelicase eIF4A. Nat. Chem. Biol. 2:213-220. http://dx.doi.org/10.1038/nchembio776.
49. Schneider-Poetsch T, Ju J, Eyler DE, Dang Y, Bhat S, Merrick WC, Green R, Shen B, Liu JO. 2010. Inhibition of eukaryotic translation elongation by cycloheximide and lactimidomycin. Nat. Chem. Biol. 6:209-217. http://dx.doi.org/10.1038/nchembio.304.
50. Spuul P, Balistreri G, Hellstrom K, Golubtsov AV, Jokitalo E, Ahola T.Assembly of alphavirus replication complexes from RNA and protein components in a novel trans-replication system in mammalian cells. J. Virol. 85:4739-4751. http://dx.doi.org/10.1128/JVI.00085-11.
51. Wang QY, Bushell S, Qing M, Xu HY, Bonavia A, Nunes S, Zhou J, Poh MK, Florez de Sessions P, Niyomrattanakit P, Dong H, Hoffmaster K, Goh A, Nilar S, Schul W, Jones S, Kramer L, Compton T, Shi PY. 2011. Inhibition of dengue virus through suppression of host pyrimidine biosynthesis. J. Virol. 85:6548-6556. http://dx.doi.org/10.1128/JVI.02510-10.
52. Bonavia A, Franti M, Pusateri Keaney E, Kuhen K, Seepersaud M, Radetich B, Shao J, Honda A, Dewhurst J, Balabanis K, Monroe J, Wolff K, Osborne C, Lanieri L, Hoffmaster K, Amin J, Markovits J, Broome M, Skuba E, Cornella-Taracido I, Joberty G, Bouwmeester T, Hamann L, Tallarico JA, Tommasi R, Compton T, Bushell SM. 2011. Identification of broad-spectrum antiviral compounds and assessment of the druggability of their target for efficacy against respiratory syncytial virus (RSV). Proc. Natl. Acad. Sci. U. S. A. 108:6739-6744. http://dx.doi.org/10.1073 /pnas.1017142108.
53. Smee DF, Hurst BL, Day CW. 2012. D282, a non-nucleoside inhibitor of influenza virus infection that interferes with de novo pyrimidine biosynthesis. Antivir. Chem. Chemother. 22:263-272. http://dx.doi.org/10.3851 /IMP2105.
54. Schoepp RJ, Smith JF, Parker MD. 2002. Recombinant chimeric western and eastern equine encephalitis viruses as potential vaccine candidates. Virology 302:299-309. http://dx.doi.org/10.1006/viro.2002.1677.
55. Gao M, Nettles RE, Belema M, Snyder LB, Nguyen VN, Fridell RA, Serrano-Wu MH, Langley DR, Sun JH, O'Boyle DR, Lemm JA, Wang C, Knipe JO, Chien C, Colonno RJ, Grasela DM, Meanwell NA, Hamann LG. 2010. Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect. Nature 465:96-100. http://dx.doi.org /10.1038/nature08960.
56. Nagy PD, Pogany J. 2012. The dependence of viral RNA replication on co-opted host factors. Nat. Rev. Microbiol. 10:137-149. http://dx.doi.org /10.1038/nrmicro2692.
57. Lucas-Hourani M, Dauzonne D, Jorda P, Cousin G, Lupan A, Helynck O, Caignard G, Janvier G, Andre-Leroux G, Khiar S, Escriou N, Despres P, Jacob Y, Munier-Lehmann H, Tangy F, Vidalain PO. 2013. Inhibition of pyrimidine biosynthesis pathway suppresses viral growth through innate immunity. PLoS Pathog. 9:e1003678. http://dx.doi.org/10.1371 /journal.ppat.1003678.
58. Kaur P, Thiruchelvan M, Lee RC, Chen H, Chen KC, Ng ML, Chu JJ. 2013. Inhibition of chikungunya virus replication by harringtonine, a novel antiviral that suppresses viral protein expression. Antimicrob. Agents Chemother. 57:155-167. http://dx.doi.org/10.1128/AAC.01467-12.
59. Garcia-Rivera JA, Bobardt M, Chatterji U, Hopkins S, Gregory MA, Wilkinson B, Lin K, Gallay PA. 2012. Multiple mutations in hepatitis C virus NS5A domain II are required to confer a significant level of resistance to alisporivir. Antimicrob. Agents Chemother. 56:5113-5121. http://dx .doi.org/10.1128/AAC.00919-12.
60. Coelmont L, Hanoulle X, Chatterji U, Berger C, Snoeck J, Bobardt M, Lim P, Vliegen I, Paeshuyse J, Vuagniaux G, Vandamme AM, Bartenschlager R, Gallay P, Lippens G, Neyts J. 2010. DEB025 (alisporivir) inhibits hepatitisCvirus replication by preventing a cyclophilinAinduced cis-trans isomerisation in domain II of NS5A. PLoS One 5:e13687. http: //dx.doi.org/10.1371/journal.pone.0013687.
61. Gallay PA, Lin K. 2013. Profile of alisporivir and its potential in the treatment of hepatitis C. Drug Des. Devel. Ther. 7:105-115. http://dx.doi .org/10.2147/DDDT.S30946.
62. Ahola T, Ka¨a¨ria¨inen L. 1995. Reaction in alphavirus mRNS capping: formation of a covalent complex of nonstructural protein nsP1 with 7-methyl-GMP. Proc. Natl. Acad. Sci. U. S. A. 92:507-511. http://dx.doi .org/10.1073/pnas.92.2.507.
63. Gomez de Cedro´n M, Ehsani N, Mikkola ML, Garcia JA, Kaariainen L. RNA helicase activity of Semliki Forest virus replicase protein nsP2. FEBS Lett. 448:19-22. http://dx.doi.org/10.1016/S0014-5793(99)00321-X.
64. Merits A, Vasiljeva L, Ahola T, Kaariainen L, Auvinen P. 2001. Proteolytic processing of Semliki Forest virus-specific non-structural polyprotein by nsP2 protease. J. Gen. Virol. 82:765-773.
65. Tomar S, Hardy RW, Smith JL, Kuhn RJ. 2006. Catalytic core of alphavirus nonstructural protein nsP4 possesses terminal adenylyltransferase activity. J. Virol. 80:9962-9969. http://dx.doi.org/10.1128/JVI.01067-06.
66. Ohse T, Ohba S, Yamamoto T, Koyano T, Umezawa K. 1996. Cyclopentabenzofuran lignan protein synthesis inhibitors from Aglaia odorata. J. Nat. Prod. 59:650-652. http://dx.doi.org/10.1021/np960346g.
67. Bleumink M, Kohler R, Giaisi M, Proksch P, Krammer PH, Li-Weber M. 2011. Rocaglamide breaks TRAIL resistance in HTLV-1-associated adult T-cell leukemia/lymphoma by translational suppression of c-FLIP expression. Cell Death Differ. 18:362-370. http://dx.doi.org/10.1038/cdd .2010.99.
68. Polier G, Neumann J, Thuaud F, Ribeiro N, Gelhaus C, Schmidt H, Giaisi M, Kohler R, Muller WW, Proksch P, Leippe M, Janssen O, Desaubry L, Krammer PH, Li-Weber M. 2012. The natural anticancer compounds rocaglamides inhibit the Raf-MEK-ERK pathway by targeting prohibitin 1 and 2. Chem. Biol. 19:1093-1104. http://dx.doi.org/10.1016 /j.chembiol.2012.07.012.
69. Beretta L, Gingras AC, Svitkin YV, Hall MN, Sonenberg N. 1996. Rapamycin blocks the phosphorylation of 4E-BP1 and inhibits capdependent initiation of translation. EMBO J. 15:658-664.
70. Rix U, Superti-Furga G. 2009. Target profiling of small molecules by chemical proteomics. Nat. Chem. Biol. 5:616-624. http://dx.doi.org/10 .1038/nchembio.216.